{"id":27864,"date":"2022-02-03T15:18:41","date_gmt":"2022-02-03T14:18:41","guid":{"rendered":"https:\/\/kymos.com\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/"},"modified":"2025-12-03T19:02:04","modified_gmt":"2025-12-03T18:02:04","slug":"acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies","status":"publish","type":"post","link":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/","title":{"rendered":"Acides nucl\u00e9iques&nbsp;: de petit poucet biologique \u00e0 star des biotechnologies"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span style=\"font-size: 14pt;\">La <a href=\"https:\/\/kymos.com\/fr\/services\/services-precliniques-et-cliniques\/bioanalyse-des-acides-nucleiques\/\" data-wpel-link=\"internal\">bioanalyse des acides nucl\u00e9iques<\/a> , notamment dans les matrices biologiques, est l&rsquo;un des services les plus r\u00e9cents propos\u00e9s par le groupe Kymos et r\u00e9alis\u00e9 par sa filiale allemande Prolytic. Maria Fauth, responsable du d\u00e9partement des oligonucl\u00e9otides, a consacr\u00e9 l&rsquo;int\u00e9gralit\u00e9 de sa carri\u00e8re, tant acad\u00e9mique qu&rsquo;industrielle, \u00e0 la recherche et \u00e0 l&rsquo;analyse des acides nucl\u00e9iques. Elle et le Dr Janine Lossie d&rsquo;OMEICOS Therapeutics partagent leurs points de vue sur ce domaine prometteur.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab D\u00e9j\u00e0 \u00e9tudiante, j\u2019\u00e9tais fascin\u00e9e par les oligonucl\u00e9otides, et plus particuli\u00e8rement par les microARN \u00bb, explique Maria Fauth. \u00ab Longtemps consid\u00e9r\u00e9s comme des mol\u00e9cules biologiquement inutiles, la communaut\u00e9 scientifique a d\u00e9couvert leurs fonctions r\u00e9gulatrices essentielles. Depuis, l\u2019importance des acides nucl\u00e9iques n\u2019a cess\u00e9 de cro\u00eetre dans le secteur de la sant\u00e9, et avec le d\u00e9but de la pand\u00e9mie de COVID-19, les vaccins \u00e0 ARNm sont devenus un enjeu majeur pour le grand public. \u00bb  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab&nbsp;C\u2019est une belle reconnaissance pour notre \u00e9quipe, qui \u00e9tudie et travaille sur l\u2019ARN depuis des d\u00e9cennies, mais c\u2019est aussi un d\u00e9fi de taille&nbsp;\u00bb, d\u00e9clare Mme Fauth. \u00ab&nbsp;Le succ\u00e8s des vaccins \u00e0 ARNm a suscit\u00e9 un vif int\u00e9r\u00eat, mais a \u00e9galement mis en \u00e9vidence la n\u00e9cessit\u00e9 d\u2019utiliser des m\u00e9thodes d\u2019analyse robustes pour la recherche sur les m\u00e9dicaments nucl\u00e9otidiques. C\u2019est pourquoi nous avons concentr\u00e9 nos efforts sur le d\u00e9veloppement et la validation de m\u00e9thodes standardis\u00e9es et reproductibles pour la quantification d\u2019une grande vari\u00e9t\u00e9 d\u2019acides nucl\u00e9iques.&nbsp;\u00bb  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">L&rsquo;analyse des biomarqueurs \u00e0 base d&rsquo;acides nucl\u00e9iques ou des m\u00e9dicaments th\u00e9rapeutiques requiert des approches bioanalytiques distinctes en raison de leurs diff\u00e9rents niveaux de concentration&nbsp;: pour la quantification des oligonucl\u00e9otides th\u00e9rapeutiques, les m\u00e9thodes ELISA ou LC-MS\/MS sont les plus appropri\u00e9es selon la sensibilit\u00e9 requise. Cependant, ces technologies sont insuffisantes pour les biomarqueurs \u00e0 des concentrations attomolaires, pour lesquels la qPCR en temps r\u00e9el devient la m\u00e9thode de r\u00e9f\u00e9rence. Maria Fauth apporte des pr\u00e9cisions&nbsp;:  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab Nous sommes ravis de pouvoir proposer toutes ces m\u00e9thodes \u2013 ELISA d\u2019hybridation, LC-MS\/MS et qPCR \u2013 dans le respect des BPL chez Prolytic. Gr\u00e2ce \u00e0 ces technologies, nous pouvons quantifier non seulement les biomarqueurs ou les agents th\u00e9rapeutiques \u00e0 base d\u2019ADN et d\u2019ARNm, mais aussi d\u2019autres outils th\u00e9rapeutiques \u00e9mergents tels que les aptam\u00e8res ou les antagomiRs, utilis\u00e9s pour moduler l\u2019expression des g\u00e8nes et influencer la progression des maladies. Nous couvrons ainsi un large \u00e9ventail d\u2019analyses d\u2019oligonucl\u00e9otides, ce que nos clients appr\u00e9cient particuli\u00e8rement \u00bb, explique-t-elle avec satisfaction.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">De fait, de nombreux acteurs pharmaceutiques mondiaux et de jeunes entreprises de biotechnologie innovantes s&rsquo;int\u00e9ressent de plus en plus \u00e0 la recherche sur les acides nucl\u00e9iques. Le Dr Janine Lossie, responsable de la pharmacologie <em>in vivo<\/em> chez OMEICOS Therapeutics et cliente de longue date de Prolytic, per\u00e7oit \u00e9galement le grand int\u00e9r\u00eat des m\u00e9thodes analytiques valid\u00e9es pour les acides nucl\u00e9iques&nbsp;: <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab Prolytic nous a accompagn\u00e9s tout au long du d\u00e9veloppement de notre mol\u00e9cule innovante OMT-28. Nous avons \u00e9t\u00e9 ravis d&rsquo;apprendre que Prolytic peut \u00e9galement mesurer les acides nucl\u00e9iques conform\u00e9ment aux BPL, car nous entrevoyons la possibilit\u00e9 de les utiliser comme biomarqueurs pour \u00e9valuer l&rsquo;efficacit\u00e9 de nos m\u00e9dicaments \u00e0 l&rsquo;avenir. Nous avons pleinement confiance dans l&rsquo;expertise de l&rsquo;\u00e9quipe de Maria Fauth et sommes convaincus que notre collaboration dans ce domaine continuera de se d\u00e9velopper. \u00bb<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Le dosage des biomarqueurs d&rsquo;acides nucl\u00e9iques selon les BPL est actuellement recommand\u00e9, mais non obligatoire. Maria Fauth est n\u00e9anmoins convaincue que, compte tenu de l&rsquo;attention croissante que la FDA et l&rsquo;EMA portent aux biomarqueurs d&rsquo;acides nucl\u00e9iques, l&rsquo;adoption de lignes directrices correspondantes n&rsquo;est qu&rsquo;une question de temps. Son \u00e9quipe s&rsquo;y est pr\u00e9par\u00e9e en cons\u00e9quence.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab Face \u00e0 une demande croissante, nous avons mis en place un syst\u00e8me de traitement automatis\u00e9 des acides nucl\u00e9iques bas\u00e9 sur la technique des battements magn\u00e9tiques et install\u00e9 un instrument qPCR multiplex \u00bb, explique Mme Fauth. \u00ab Gr\u00e2ce \u00e0 cela, nous sommes d\u00e9sormais en mesure d&rsquo;atteindre des d\u00e9bits bien sup\u00e9rieurs et de r\u00e9pondre aux besoins futurs de nos clients. \u00bb Maria Fauth conclut : \u00ab C&rsquo;est un v\u00e9ritable plaisir pour moi de constater que la discipline scientifique \u00e0 laquelle j&rsquo;ai consacr\u00e9 des ann\u00e9es de ma carri\u00e8re conna\u00eet aujourd&rsquo;hui un d\u00e9veloppement aussi spectaculaire. Mon \u00e9quipe et moi-m\u00eame appr\u00e9cions tout particuli\u00e8rement l&rsquo;esprit d&rsquo;innovation qui r\u00e8gne chez Prolytic et Kymos et nous avons h\u00e2te de d\u00e9couvrir tous les projets passionnants \u00e0 venir. \u00bb   <\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 14pt;\">OMEICOS Therapeutics est une soci\u00e9t\u00e9 biopharmaceutique qui d\u00e9veloppe des traitements novateurs \u00e0 base de petites mol\u00e9cules pour la pr\u00e9vention et le traitement des maladies cardiovasculaires et autres maladies associ\u00e9es \u00e0 l&rsquo;inflammation et au dysfonctionnement mitochondrial. Pour plus d&rsquo;informations, consultez le site <a href=\"http:\/\/www.omeicos.com\" data-wpel-link=\"external\">www.omeicos.com<\/a> ou contactez-nous \u00e0 l&rsquo; <a href=\"mailto:info@omeicos.com\" data-wpel-link=\"internal\">adresse info@omeicos.com<\/a> . <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":27872,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[257],"tags":[62],"class_list":["post-27864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalyse","tag-joan"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos<\/title>\n<meta name=\"description\" content=\"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d&#039;acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos\" \/>\n<meta property=\"og:description\" content=\"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d&#039;acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-03T14:18:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-03T18:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1292\" \/>\n\t<meta property=\"og:image:height\" content=\"714\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Acides nucl\u00e9iques&nbsp;: de petit poucet biologique \u00e0 star des biotechnologies\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-12-03T18:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/\"},\"wordCount\":998,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"keywords\":[\"joan\"],\"articleSection\":[\"Bioanalyse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/\",\"name\":\"Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"datePublished\":\"2022-02-03T14:18:41+00:00\",\"dateModified\":\"2025-12-03T18:02:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d'acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/2022-02-05-Nucleic-Acids_Banner2_small.png\",\"width\":1292,\"height\":714,\"caption\":\"Nucleic Acids\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acides nucl\u00e9iques&nbsp;: de petit poucet biologique \u00e0 star des biotechnologies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos","description":"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d'acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/","og_locale":"fr_FR","og_type":"article","og_title":"Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos","og_description":"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d'acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!","og_url":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/","og_site_name":"Kymos","article_published_time":"2022-02-03T14:18:41+00:00","article_modified_time":"2025-12-03T18:02:04+00:00","og_image":[{"width":1292,"height":714,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"\u00c9crit par":"Joan Puig de Dou","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Acides nucl\u00e9iques&nbsp;: de petit poucet biologique \u00e0 star des biotechnologies","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-12-03T18:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/"},"wordCount":998,"image":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","keywords":["joan"],"articleSection":["Bioanalyse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/","url":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/","name":"Acides nucl\u00e9iques\u00a0: biomarqueurs ou m\u00e9dicaments th\u00e9rapeutiques\u00a0? | Groupe Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","datePublished":"2022-02-03T14:18:41+00:00","dateModified":"2025-12-03T18:02:04+00:00","author":{"@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Maria Fauth et le Dr Lossie (OMEICOS) parlent des biomarqueurs \u00e0 base d'acides nucl\u00e9iques et des m\u00e9dicaments th\u00e9rapeutiques. Pour en savoir plus\u00a0!","breadcrumb":{"@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2022\/02\/2022-02-05-Nucleic-Acids_Banner2_small.png","width":1292,"height":714,"caption":"Nucleic Acids"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/fr\/news\/acides-nucleiques-de-petit-poucet-biologique-a-star-des-biotechnologies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Acides nucl\u00e9iques&nbsp;: de petit poucet biologique \u00e0 star des biotechnologies"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/fr\/#website","url":"https:\/\/kymos.com\/fr\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/fr\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/comments?post=27864"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media\/27872"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media?parent=27864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/categories?post=27864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/tags?post=27864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}